December 30, (THEWILL) – President Muhammadu Buhari has approved the reappointment of Prof. Mojisola Adeyeye, as the Director General of the National Agency for Food and Drug Administration and Control (NAFDAC).
Adeyeye, a Nigerian pharmacist and professor, was first appointed Director-General of NAFDAC on November 3, 2017, by President Buhari, for a period of 5 years. She ended her first term of office on November 2, 2022.
Following the expiration of the first tenure as the DG, the Director of Drug Registration and Regulatory Affairs Directorate of NAFDAC, Dr Monica Eimunjeze, took over as the Acting DG of the Agency on November 12, 2022.
But a tweet on the official Twitter handle of the agency on Friday, revealed that Adeyeye’s appointment had been renewed for another 5 years.
“Prof. Mojisola Christianah Adeyeye has been reappointed as the @DGatNAFDAC for the second and final tenure of five years. She stopped by briefly at the corporate headquarters in Abuja to meet with some Directors”, the tweet read.
A senior staff in the agency, who craved anonymity, said her reappointment took effect from December 1, 2022.
Before her appointment as NAFDAC boss in 2017, Prof Adeyeye was the founding Chair of Biopharmaceutical Sciences and a Professor of Pharmaceutics, Manufacturing Science and Drug Product Evaluation at the College of Pharmacy, Roosevelt University in Schaumburg, Illinois, where she spent 7 years.
She was also a Professor of Pharmaceutics and Manufacturing for 21 years at Duquesne University in Pittsburgh, Pennsylvania, USA. She is a Senior Fulbright Scholar and Specialist and 2008 American Association of Pharmaceutical Scientists Fellow (the first African woman fellow).
Adeyeye is a Fellow of the Nigerian Academy of Science and Nigeria Academy of Pharmacy. Her research interests are in pre-formulation, early-phase development of solid, semisolid and liquid dosage forms, and IND-based and intellectual property-driven late-phase drug product development.
She is the founder and President of Elim Pediatric Pharmaceuticals Rolling Meadows, Illinois. Through Duquesne University, she developed an anti-retroviral (HIV/AIDS) pediatric fixed-dose combination and received intellectual property on the formulations in the UK and South Africa.
About the Author
